CY1108670T1 - Αναλογα λιποξινης ως νεοι αναστολεις αγγειογενεσης - Google Patents

Αναλογα λιποξινης ως νεοι αναστολεις αγγειογενεσης

Info

Publication number
CY1108670T1
CY1108670T1 CY20081101498T CY081101498T CY1108670T1 CY 1108670 T1 CY1108670 T1 CY 1108670T1 CY 20081101498 T CY20081101498 T CY 20081101498T CY 081101498 T CY081101498 T CY 081101498T CY 1108670 T1 CY1108670 T1 CY 1108670T1
Authority
CY
Cyprus
Prior art keywords
suspensions
lxa
lipoxin analogs
new angiogenesis
epi
Prior art date
Application number
CY20081101498T
Other languages
Greek (el)
English (en)
Inventor
Charles N Serhan
Iolanda M Fierro
Original Assignee
The Brigham And Women΄S Hospital, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham And Women΄S Hospital, Inc. filed Critical The Brigham And Women΄S Hospital, Inc.
Publication of CY1108670T1 publication Critical patent/CY1108670T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20081101498T 2001-03-02 2008-12-29 Αναλογα λιποξινης ως νεοι αναστολεις αγγειογενεσης CY1108670T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27293101P 2001-03-02 2001-03-02
EP02721234A EP1406698B1 (en) 2001-03-02 2002-03-01 Lipoxin analogs as novel inhibitors of angiogenesis
US10/086,609 US6627658B2 (en) 2001-03-02 2002-03-01 Lipoxin analogs as novel inhibitors of angiogenesis

Publications (1)

Publication Number Publication Date
CY1108670T1 true CY1108670T1 (el) 2014-04-09

Family

ID=26774943

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101498T CY1108670T1 (el) 2001-03-02 2008-12-29 Αναλογα λιποξινης ως νεοι αναστολεις αγγειογενεσης

Country Status (11)

Country Link
US (4) US6627658B2 (enExample)
EP (2) EP1406698B1 (enExample)
JP (3) JP2005508282A (enExample)
AT (1) ATE412448T1 (enExample)
AU (1) AU2002252175A1 (enExample)
CY (1) CY1108670T1 (enExample)
DE (1) DE60229640D1 (enExample)
DK (1) DK1406698T3 (enExample)
ES (1) ES2316553T3 (enExample)
PT (1) PT1406698E (enExample)
WO (1) WO2002070068A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762557B1 (en) 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
EP1268393A2 (en) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
EP1406698B1 (en) * 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
AU2003258194B2 (en) * 2002-08-12 2009-11-12 The Brigham And Women's Hospital, Inc. Resolvins: biotemplates for therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
BRPI0517972A (pt) * 2004-11-09 2008-10-21 Alcon Inc ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US8636986B2 (en) * 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
AU2007243282A1 (en) * 2006-04-28 2007-11-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
MX2009000657A (es) * 2006-07-19 2009-05-28 Resolvyx Pharmaceuticals Inc Composiciones y metodos para el tratamiento de mucositis.
US20080161274A1 (en) * 2006-10-26 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compounds and methods for inhibition of bone loss
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
TW200915984A (en) * 2007-08-08 2009-04-16 Basf Se Aqueous microemulsions containing organic insecticide compounds
WO2009038671A2 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases
EP2214660A2 (en) * 2007-10-12 2010-08-11 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for the treatment of ophthalmic conditions
US20100324138A1 (en) * 2007-10-29 2010-12-23 Bazan Nicolas G Lipoxin A4 Protection for Retinal Cells
US7601693B2 (en) * 2008-02-05 2009-10-13 National Taiwan University Composition for treating cancer and use thereof
US20100105772A1 (en) * 2008-04-25 2010-04-29 Serhan Charles N Use of novel lipid mediators to inhibit angiogenesis
CA2902232C (en) * 2013-02-22 2020-12-29 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
JP2016509863A (ja) * 2013-03-15 2016-04-04 ラーソン、マルクス カーレ、トールレイフＬＡＲＳＳＯＮ， Ｍａｒｃｕｓ Ｋａｒｅ， Ｔｏｒｌｅｉｆ 細胞、臍帯血収集のための方法及び装置、並びに細胞の単離のための方法及び装置
EP3020398A1 (en) * 2014-11-17 2016-05-18 Nitto Denko Corporation Compounds and formulations for reducing scarring
CA3026264A1 (en) 2016-06-03 2017-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
WO2018073615A1 (en) 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
CN110709138A (zh) 2017-01-31 2020-01-17 布里格姆及妇女医院股份有限公司 Alx受体配体定义炎症性疾病的生化内型
US11439615B2 (en) * 2017-03-09 2022-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2020256628A1 (en) 2019-06-20 2020-12-24 Amniotics Ab An apparatus for filtering amniotic fluid
JP7714535B2 (ja) 2019-10-18 2025-07-29 アムニオティクス・アーベー 羊水およびそれに由来する細胞から羊水間葉系幹細胞を得るためのプロセスならびに装置
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
WO2023168245A2 (en) 2022-03-03 2023-09-07 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560514A (en) 1984-05-04 1985-12-24 Bengt Samuelsson Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4780281A (en) 1985-06-14 1988-10-25 Wayne State University Method for assay of peroxidase enzyme or reducing substrate activity
JPS62198677A (ja) 1986-02-26 1987-09-02 Nissan Chem Ind Ltd テトラオ−ル誘導体
JPH0739368B2 (ja) 1986-10-01 1995-05-01 旭硝子株式会社 ２０，２０，２０−トリフルオロアラキドン酸誘導体およびその製造法
CA1329809C (en) 1987-07-08 1994-05-24 Nissan Chemical Industries, Ltd. Optically active allyl alcohol and process for producing leucotriene b_ using thereof
JPH01228994A (ja) 1988-03-10 1989-09-12 Fumie Satou γ−シリルアリルアルコール及びその製造法
US5079261A (en) 1989-04-28 1992-01-07 Brigham And Women's Hospital Use of lipoxin a4 and its derivatives as antagonists for slow-reacting substances of anaphylaxis
JP2834512B2 (ja) 1990-01-30 1998-12-09 帝人株式会社 リポキシン誘導体を有効成分とする疾患治療剤
US5322699A (en) 1991-02-04 1994-06-21 The Rockefeller University Leukocyte-derived CR3 modulator, integrin modulating factor-1 (IMF-1)
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
JP3227922B2 (ja) 1993-01-20 2001-11-12 富士電機株式会社 自動販売機
US6048897A (en) * 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
DE69435125D1 (de) * 1993-06-15 2008-10-02 Brigham & Womens Hospital Lipoxinverbindungen mit verlängerter halbwertszeit
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
US5750354A (en) 1994-03-11 1998-05-12 Brigham And Women's Hospital Lipoxin transport system and uses therefor
DE69703121D1 (de) * 1996-10-25 2000-10-19 Us Health Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
JP2002522540A (ja) * 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
CA2615917C (en) * 1999-03-18 2011-10-04 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alpha)initiated neutrophil response
CA2365204C (en) * 1999-03-18 2009-10-27 Brigham And Women's Hospital Lipoxin compounds and their use
EP1762557B1 (en) * 2000-02-16 2011-04-06 The Brigham And Women's Hospital, Inc. Aspirin-triggered lipid mediators
EP1268393A2 (en) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
EP1406698B1 (en) 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis

Also Published As

Publication number Publication date
US8008282B2 (en) 2011-08-30
EP1406698B1 (en) 2008-10-29
US20060009521A1 (en) 2006-01-12
US20040053998A1 (en) 2004-03-18
JP2005508282A (ja) 2005-03-31
US6627658B2 (en) 2003-09-30
US20080064749A1 (en) 2008-03-13
AU2002252175A1 (en) 2002-09-19
WO2002070068A3 (en) 2003-12-31
DK1406698T3 (da) 2009-02-09
DE60229640D1 (de) 2008-12-11
EP2221089A1 (en) 2010-08-25
JP5302856B2 (ja) 2013-10-02
EP1406698A2 (en) 2004-04-14
WO2002070068A2 (en) 2002-09-12
ATE412448T1 (de) 2008-11-15
JP2012255025A (ja) 2012-12-27
ES2316553T3 (es) 2009-04-16
US20020193431A1 (en) 2002-12-19
JP2010059183A (ja) 2010-03-18
PT1406698E (pt) 2009-01-12

Similar Documents

Publication Publication Date Title
PT1406698E (pt) Análogos de lipoxina como novos inibidores da angiogénese
MX9704671A (es) Esteres y amidas de acidos carboxilicos antiinflamatorios no esteroidales que pueden usarse como antioxidantes, inhibidores de 5-lipoxigenasa y productos antiiflamatorios no esteroidales.
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
BR9810841A (pt) Inibidores de metaloprotease alicìclicos
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
NO941361L (no) 1H-indol-3-acetamid sPLA2-inhibitorer
EP0699439A3 (en) Treatment of diseases caused by sebum with inhibitors of acyl CoA cholesterol acyltransferase
AU8830801A (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
BG105163A (bg) Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания
BG106407A (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
BG105953A (bg) Метод за лечение на хронична обструктивна белодробна болест
WO2001003688A3 (en) Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
DE60236467D1 (de) Lipoxinanaloge als neuartige Restenose-Hemmer
ATE248607T1 (de) Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen
AP2003002905A0 (en) Sertraline salts and sustained-release dosage forms of sertraline.